Topics

CAR Natural Killer Cell Therapy Safe and Effective in First Trial.

08:00 EDT 10th March 2020 | BioPortfolio

Summary of "CAR Natural Killer Cell Therapy Safe and Effective in First Trial."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: JAMA
ISSN: 1538-3598
Pages: 916

Links

DeepDyve research library

PubMed Articles [37421 Associated PubMed Articles listed on BioPortfolio]

Overexpressed CXCR4 and CCR7 on the surface of NK92 cell have improved migration and anti-tumor activity in human colon tumor model.

Successive infusion of natural killer cells is increasingly being explored as a treatment for cancer patients. The inadequate homing of natural killer cells into the tumor site resulted in the poor ef...

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the...

Clinical Impact of the Bolus in Intensity-Modulated Radiotherapy and Volumetric-Modulated Arc Therapy for Stage I-II Nasal Natural Killer/T-Cell Lymphoma.

To estimate the clinical impact of bolus in intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) for stage I-II nasal natural killer/T-cell lymphoma (NNKTCL), including ...

Human STAT5b mutation causes dysregulated human natural killer cell maturation and impaired lytic function.

Patients with STAT5b deficiency have autoimmunity, recurrent infections and combined immune deficiency, which affects T-cell homeostasis and leads to natural killer (NK) cell impairment.

Efficient ADCC- killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Meningiomas are the most common adult primary tumor of the central nervous system, but there are no known effective medical therapies for recurrent meningioma, particularly for WHO grade II and III tu...

Clinical Trials [21716 Associated Clinical Trials listed on BioPortfolio]

Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor

Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype. Our hypothesis is that Natural killer T cells may decrease the tumor burden and improve...

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with met...

Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based immunotherapy in subjects with non small cell lung can...

Assessment of Natural Killer Cells in Unexplained Recurrent Pregnancy Loss

To assess natural killer cells frequency and activation in cases of unexplained recurrent abortion in comparison to fertile cases - 2. . To study the expression of stimulatory receptor...

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed Neuroblastoma Post Autologous Stem Cell Transplant

Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2). Secon...

Medical and Biotech [MESH] Definitions

Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.

Receptors that are specifically found on the surface of NATURAL KILLER CELLS. They play an important role in regulating the cellular component of INNATE IMMUNITY.

Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.

Providing an investigational therapy to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Compassionate use trials allow patients to receive promising but not yet fully studied or approved therapies when no other treatment option exists. Also called expanded access trial.

A specialized subset of T-LYMPHOCYTES that exhibit features of INNATE IMMUNITY similar to that of NATURAL KILLER CELLS. They are reactive to glycolipids presented in the context of the major histocompatibility complex (MHC) class I-like molecule, CD1D ANTIGEN.

Quick Search


DeepDyve research library

Searches Linking to this Article